000726768 000__ 03768cam\a2200457Ii\4500
000726768 001__ 726768
000726768 005__ 20230306140838.0
000726768 006__ m\\\\\o\\d\\\\\\\\
000726768 007__ cr\cn\nnnunnun
000726768 008__ 150428s2015\\\\sz\\\\\\ob\\\\001\0\eng\d
000726768 020__ $$a9783319179728$$qelectronic book
000726768 020__ $$a3319179721$$qelectronic book
000726768 020__ $$z9783319179711
000726768 0247_ $$a10.1007/978-3-319-17972-8$$2doi
000726768 035__ $$aSP(OCoLC)ocn908103270
000726768 035__ $$aSP(OCoLC)908103270
000726768 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dE7B$$dYDXCP$$dCOO$$dOCLCO$$dIDEBK$$dUWO$$dEBLCP$$dCDX
000726768 049__ $$aISEA
000726768 050_4 $$aRC271.E7
000726768 08204 $$a616.99/4061
000726768 24500 $$aResistance to aromatase inhibitors in breast cancer$$h[electronic resource] /$$cAlexey Larionov, editor.
000726768 264_1 $$aCham :$$bSpringer,$$c[2015]
000726768 300__ $$a1 online resource.
000726768 336__ $$atext$$btxt$$2rdacontent
000726768 337__ $$acomputer$$bc$$2rdamedia
000726768 338__ $$aonline resource$$bcr$$2rdacarrier
000726768 4901_ $$aResistance to targeted anti-cancer therapeutics,$$x2196-551x ;$$vvolume 8
000726768 504__ $$aIncludes bibliographical references and index.
000726768 506__ $$aAccess limited to authorized users.
000726768 520__ $$aThe book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs). The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protein, including tissue-specific splicing and regulation of the gene, crystal structure of the enzyme, functioning of its active site and structural basis for development of new aromatase inhibitors. Experimental and pre-clinical models of resistance to aromatase inhibitors (including cell lines and xenografts) as well as methods and results of measuring oestrogen concentrations in blood and tumour tissue of breast cancer patients. Diversity of molecular mechanisms of AI resistance, including (i) ligand-independent signalling through oestrogen receptor pathway, (ii) hypersensitivity to low concentrations of oestrogens, (iii) crosstalk with non-endocrine signalling (including PI3K/mTOR, IGF, GDNF and Myc pathways), (iv) involvement of oestrogen-induced apoptosis and tissue microenvironment (including inflammatory immune cells and adipocytes) as well as (v) the role of epigenetic mechanisms and pioneering factors in ER signalling and AI resistance. Molecular markers and multi-gene signatures to predict response to AIs, clinical trials aimed at preventing or overcoming resistance by combining AIs with novel targeted agents (including AI combinations with HER2, EGFR, mTOR, PI3K, Akt, CDK4/6, FGFR, HDAC, IGF-1, Src, proteosome- and angiogenic- targeting agents). A review of the effects and clinical indications of aromatase inhibitors beyond breast cancer. Many of the chapters provide extensive historical overviews to connect current knowledge with the history and inner logic of the field. The authors{u2019} team includes world-leading experts, making the book an essential resource for scientists developing new treatments for breast cancer and for medics treating breast cancer patients with aromatase inhibitors.
000726768 588__ $$aOnline resource; title from PDF title page (viewed May 1, 2015).
000726768 650_0 $$aAromatase$$xAntagonists$$xTherapeutic use.
000726768 650_0 $$aDrug resistance in cancer cells.
000726768 650_0 $$aBreast$$xCancer$$xChemotherapy.
000726768 7001_ $$aLarionov, Alexey,$$eeditor.
000726768 77608 $$iPrint version:$$z9783319179711
000726768 830_0 $$aResistance to targeted anti-cancer therapeutics ;$$vv. 8.
000726768 852__ $$bebk
000726768 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-17972-8$$zOnline Access$$91397441.1
000726768 909CO $$ooai:library.usi.edu:726768$$pGLOBAL_SET
000726768 980__ $$aEBOOK
000726768 980__ $$aBIB
000726768 982__ $$aEbook
000726768 983__ $$aOnline
000726768 994__ $$a92$$bISE